scholarly journals A distinctive bullous skin reaction associated with enfortumab vedotin‐ejfv treatment for metastatic urothelial cancer: A case report

2021 ◽  
Author(s):  
Torben Krause ◽  
Hanna Bonnekoh ◽  
Amrei Dilling ◽  
Alexander Nast ◽  
Martin Metz
Keyword(s):  
Case Report ◽  
Skin Reaction ◽  
Urothelial Cancer ◽  
Metastatic Urothelial Cancer

Dexmedetomidine withdrawal syndrome and opioid sensitivity

2020 ◽  
pp. bmjspcare-2020-002705
Author(s):  
Lana Ferguson ◽  
Stacey Hooper
Keyword(s):  
Case Report ◽  
Pain Management ◽  
Cancer Pain ◽  
Withdrawal Syndrome ◽  
Urothelial Cancer ◽  
Cancer Pain Management ◽  
Metastatic Urothelial Cancer ◽  
Opioid Sensitivity

This case report describes the use of dexmedetomidine for refractory cancer pain management in a patient with significant pelvic disease due to metastatic urothelial cancer. Specifically, the management of increased opioid sensitivity secondary to dexmedetomidine is discussed. Further, the phenomenon of dexmedetomidine withdrawal syndrome and our management of this is addressed.

scholarly journals Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single‐center analysis in Japan

2021 ◽  
Author(s):  
Motohiro Fujiwara ◽  
Takeshi Yuasa ◽  
Tetsuya Urasaki ◽  
Yoshinobu Komai ◽  
Ryo Fujiwara ◽  
...  
Keyword(s):  
Safety Profile ◽  
Urothelial Cancer ◽  
Single Center ◽  
Metastatic Urothelial Cancer

scholarly journals Second-Line Therapy In Patients with Locally Advanced or Metastatic Urothelial Cancer: A Systematic Literature Review

2017 ◽  
Vol 20 (9) ◽  
pp. A414
Author(s):  
M Bharmal ◽  
S Guenther ◽  
G Rosen ◽  
M Kearney ◽  
H Phatak ◽  
...  
Keyword(s):  
Literature Review ◽  
Systematic Literature Review ◽  
Urothelial Cancer ◽  
Locally Advanced ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Metastatic Urothelial Cancer

Docetaxel and cisplatin (DC) combination chemotherapy for metastatic urothelial cancer

1997 ◽  
Vol 33 ◽  
pp. S35 ◽  
Author(s):  
M. Dimopoulos ◽  
G. Louras ◽  
D. Pantazopoulos ◽  
C. Deliveliotis ◽  
C. Constantinidis ◽  
...  
Keyword(s):  
Combination Chemotherapy ◽  
Urothelial Cancer ◽  
Metastatic Urothelial Cancer

scholarly journals Aripiprazole induced severe and extensive skin reaction: A case report

2012 ◽  
Vol 2 (5) ◽  
pp. 195-198 ◽  
Author(s):  
Caroline Parker
Keyword(s):  
Case Report ◽  
Skin Reaction

scholarly journals Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma

2012 ◽  
Vol 30 (28) ◽  
pp. 3545-3551 ◽  
Author(s):  
Yu-Ning Wong ◽  
Samuel Litwin ◽  
David Vaughn ◽  
Seth Cohen ◽  
Elizabeth R. Plimack ◽  
...  
Keyword(s):  
Phase Ii ◽  
Urothelial Cancer ◽  
Single Agent ◽  
Progression Free Survival ◽  
Salvage Chemotherapy ◽  
Free Survival ◽  
Metastatic Urothelial Cancer ◽  
Metastatic Setting ◽  
Previously Treated ◽  
Grade 3

Purpose The benefit of salvage chemotherapy is modest in metastatic urothelial cancer. We conducted a randomized, noncomparative phase II study to measure the efficacy of cetuximab with or without paclitaxel in patients with previously treated urothelial cancer. Patients and Methods Patients with metastatic urothelial cancer who received one line of chemotherapy in the perioperative or metastatic setting were randomly assigned to 4-week cycles of cetuximab 250 mg/m2 with or without paclitaxel 80 mg/m2 per week. We used early progression as an indicator of futility. Either arm would close if seven of the initial 15 patients in that arm progressed at the first disease evaluation at 8 weeks. Results We enrolled 39 evaluable patients. The single-agent cetuximab arm closed after nine of the first 11 patients progressed by 8 weeks. The combination arm completed the full accrual of 28 patients, of whom 22 patients (78.5%) had visceral disease. Twelve of 28 patients had progression-free survival greater than 16 weeks. The overall response rate was 25% (95% CI, 11% to 45%; three complete responses and four partial responses). The median progression-free survival was 16.4 weeks (95% CI, 12 to 25.1 weeks), and the median overall survival was 42 weeks (95% CI, 30.4 to 78 weeks). Treatment-related grade 3 and 4 adverse events that occurred in at least two patients were rash (six cases), fatigue (five cases), and low magnesium (three cases). Conclusion Although it had limited activity as a single agent, cetuximab appears to augment the antitumor activity of paclitaxel in previously treated urothelial cancers. The cetuximab and paclitaxel combination merits additional study to establish its role in the treatment of urothelial cancers.

Sign in / Sign up

Export Citation Format

Share Document